Bicycle Therapeutics PLC Form 4 insider transactions

Travis Alvin Thompson, Chief Financial Officer of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Michael Charles Ferguson Hannay, CHIEF PROD & SUPPLY CHAIN OFF of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Michael Skynner, CHIEF SCIENTIFIC OFFICER of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Jennifer Scott Perry, Chief Operating Officer of Bicycle Therapeutics Plc, received 60,000 shares of common stock on July 15, 2026.

Jennifer Scott Perry, Chief Operating Officer of Bicycle Therapeutics PLC, reported transactions involving the sale of ordinary shares.

Michael Skynner, Chief Scientific Officer at Bicycle Therapeutics, reported transactions involving the sale of company shares to cover tax withholding obligations.

Bicycle Therapeutics CEO Kevin Lee reported the sale of 7,642 ordinary shares, a transaction related to tax withholding obligations upon RSU vesting.

Michael Hannay, Chief Prod & Supply Chain Officer at Bicycle Therapeutics PLC, reported the sale of 1,761 ordinary shares on July 2nd and July 6th, 2026.

Bicycle Therapeutics PLC reports a Form 4 filing detailing stock transactions by Chief Financial Officer Travis Alvin Thompson.

Michael Hannay, Chief Prod & Supply Chain Officer at Bicycle Therapeutics PLC, reported the sale of 1,521 ordinary shares on April 2, 2026, and an additional 251 shares on April 6, 2026.

Bicycle Therapeutics' Chief Financial Officer, Travis Thompson, reported the sale of shares to cover tax withholding obligations.

Jennifer Scott Perry, Chief Operating Officer of Bicycle Therapeutics PLC, reported transactions involving the sale of ordinary shares.

Bicycle Therapeutics CEO Kevin Lee reported the sale of 7,683 ordinary shares, primarily to cover tax withholding obligations.

Michael Skynner, Chief Scientific Officer at Bicycle Therapeutics, reported the sale of 1,879 ordinary shares on April 2, 2026, and an additional 525 shares on April 6, 2026.

Bicycle Therapeutics CFO Travis Thompson was granted 58,000 employee stock options with an exercise price of $6.49, vesting over four years.

Bicycle Therapeutics' Chief Accounting Officer, Travis Thompson, was granted 37,500 restricted share units and 75,000 stock options, alongside mandated 'sell to cover' transactions for tax obligations.

Bicycle Therapeutics' Chief Technology Officer, Michael Skynner, reported the acquisition of new equity awards and subsequent 'sell to cover' transactions for tax obligations.

Bicycle Therapeutics' Chief Product & Supply Chain Officer, Michael Charles Ferguson Hannay, was granted 50,000 restricted share units and 100,000 stock options, while also selling shares to cover tax obligations.

Alistair Milnes, COO of Bicycle Therapeutics, reported the acquisition of restricted share units and stock options, alongside sales to cover tax obligations.

Bicycle Therapeutics CFO Alethia Young reported the acquisition of restricted stock units and stock options, alongside 'sell to cover' transactions for tax obligations.

Bicycle Therapeutics CEO Kevin Lee reported the acquisition of restricted stock units and stock options, alongside mandated 'sell to cover' transactions for tax obligations.

Bicycle Therapeutics PLC director Stephen H. Sands was granted 9,500 restricted share units and options to purchase 19,000 ordinary shares.

Bicycle Therapeutics PLC Director Alessandro Riva was granted 7,380 restricted share units and options to purchase 14,761 ordinary shares.

Bicycle Therapeutics PLC director Roger D. Dansey received an award of 3,032 restricted share units and 6,065 stock options.

Bicycle Therapeutics PLC Director Gregory Paul Winter was granted 9,500 restricted share units and 19,000 stock options, vesting throughout 2026.

Bicycle Therapeutics PLC director Herve Hoppenot was granted 3,032 restricted share units and options to purchase 6,065 ordinary shares, effective January 2, 2026.

Bicycle Therapeutics PLC director Janice Bourque was granted 9,500 restricted share units and options to purchase 19,000 ordinary shares.

Bicycle Therapeutics director Jose-Carlos Gutierrez-Ramos acquired 9,500 restricted share units and 19,000 stock options.

Robert Charles Swanton, a Director at Bicycle Therapeutics PLC, was granted 3,726 restricted share units and options to purchase 7,453 ordinary shares.

Baker Bros. Advisors LP and affiliated entities reported the acquisition of restricted share units and share options in Bicycle Therapeutics PLC for director Felix J. Baker.